A study that includes 20 years of follow-up does not support aggressive treatment for localized, low-grade prostate cancer, with data indicating a small risk of progression of this grade of cancer, according to a study in the May 4 issue of JAMA.
To determine the need for treatment of localized prostate cancer, patients and physicians must understand the natural history of this disease, according to background information in the article. A recent study suggested an increasing prostate cancer death rate for men who are alive more than 15 years following diagnosis. The appropriate therapy for men with clinically localized prostate cancer has been uncertain.
Peter C. Albertsen, M.D., M.S., of the University of Connecticut Health Center, Farmington, Conn., and colleagues conducted a study to determine whether prostate cancer death rates declined, remained constant, or increased after 15 years. The researchers used data from the Connecticut Tumor Registry, supplemented by hospital record and histology review of 767 men aged 55 to 74 years with clinically localized prostate cancer diagnosed between January 1, 1971, and December 31, 1984. Patients were treated with either observation or immediate or delayed androgen withdrawal therapy, with an observation period of 24 years being the norm.
Carolyn Pennington | EurekAlert!
New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia
New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
18.08.2017 | Life Sciences
18.08.2017 | Physics and Astronomy
18.08.2017 | Materials Sciences